登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 2026年1月7日，公司实际控制人之一袁建华减持广州洁特生物过滤股份有限公司（以下简称"公司"） 可转换公司债券（以下简称"可转债"）200,000张，占公司可转债总量4,399,430张的比例为4.55%；因本 次减持公司可转债，导致其拥有公司的合并权益比例由29.26%下降至27.86%，变动1.40%。 公司收到实际控制人袁建华先生的通知，2026年1月7日袁建华通过大宗交易方式合计减持公司可转债 200,000张，占公司可转债总量4,399,430张的比例为4.55%；因本次减持公司可转债，导致其拥有公司的 合并权益比例由29.26%下降至27.86%，变动1.40%。因上述人员减持公司可转债，导致公司实际控制人 及其一致行动人拥有公司的合并权益比例由44.37%下降至42.05%，变动2.32%。现将有关权益变动情况 公告如下： 一、本次权益变动情况 （一）本次权益变动基本情况 ■ 注：根据《上市 ...

实际控制人之一减持可转换公司债券暨 权益变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688026 证券简称：洁特生物 公告编号：2026-003 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司关于 （二）本次权益变动前后情况 1、本次权益变动前： ● 2026年1月7日，公司实际控制人之一袁建华减持广州洁特生物过滤股份有限公司（以下简称"公司"） 可转换公司债券（以下简称"可转债"）200,000张，占公司可转债总量4,399,430张的比例为4.55%；因本 次减持公司可转债，导致其拥有公司的合并权益比例由29.26%下降至27.86%，变动1.40%。 ● 因上述人员减持公司可转债，导致公司实际控制人及其一致行动人拥有公司的合并权益比例由44.37% 下降至42.05%，变动2.32%。 ● 公司实际控制人及其一致行动人实际拥有的公司股份未发生变化。 ● 本次权益变动系可转债大宗交易减持，不触及要 ...

证券代码：688026 证券简称：洁特生物 公告编号：2026-001 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本季度转股情况：公司向不特定对象发行可转换公司债券证券"洁特转债"自2023年1月4日起可转换为 公司股份。自2025年10月1日至2025年12月31日期间，"洁特转债"共有人民币0.00元已转换为公司股 票，转股数量为0股，占"洁特转债"转股前公司已发行股份总额的0.00%。 ● 累计转股情况：截至2025年12月31日，"洁特转债"累计有人民币57,000元已转换为公司股票，转股数 量为1,185股，占"洁特转债"转股前公司已发行股份总额的0.00084%。 因公司办理完成2021年限制性股票激励计划第一个归属期第一次归属登记以及实施2022年年度权益分派 方案，"洁特转债"的转股价格自2023年6月6日起由48.23元/股调整为48.09元/股，具体内容详见公司于 2023年5 ...

Core Viewpoint - The company has decided not to lower the conversion price of its convertible bonds despite triggering the downward adjustment clause due to stock price performance [6][11]. Group 1: Board Meeting Decisions - The fourth board meeting of the company was held on November 21, 2025, with all seven directors present, and the decision was made to not adjust the conversion price of the "Jiet Bio" convertible bonds [1][2]. - The decision was made with a vote of 4 in favor, 0 against, and 0 abstentions [2]. Group 2: Convertible Bond Details - The "Jiet Bio" convertible bonds were issued in 2022, with a total of 4.4 million bonds at a face value of 100 RMB each, raising a total of 440 million RMB [8]. - The initial conversion price was set at 48.23 RMB per share, which has been adjusted multiple times due to various corporate actions [9]. Group 3: Price Adjustment Clause - The downward adjustment clause for the conversion price is triggered when the stock price is below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [10]. - As of the announcement date, the stock price had indeed triggered this clause, but the board decided against making any adjustments for the next three months [11].

Core Viewpoint - The company is potentially triggering a downward adjustment of the conversion price for its convertible bonds due to stock prices falling below a specified threshold, which may impact investor decisions and the company's financial strategy [2][8]. Convertible Bond Issuance - The company issued a total of 4.4 million convertible bonds with a face value of 100 RMB each, raising a total of 440 million RMB, with a maturity period from June 28, 2022, to June 27, 2028 [2][3]. - The initial conversion price was set at 48.23 RMB per share, which was adjusted to 48.09 RMB on June 6, 2023, and will further adjust to 48.02 RMB on July 4, 2024, and to 47.95 RMB on July 2, 2025, due to annual equity distribution plans [3][4]. Conversion Price Adjustment Conditions - The conversion price can be adjusted downward if the company's stock price falls below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [5][6]. - The potential trigger for this adjustment is set to begin on November 3, 2025, with a threshold price of 40.76 RMB per share [8]. Adjustment Procedure - If the company decides to adjust the conversion price, it will announce the details, including the adjustment range and the record date for shareholders, through the Shanghai Stock Exchange [7].

Core Points - Jiet Bio announced that from November 3 to November 14, 2025, its stock has closed below 85% of the current conversion price for 10 trading days, which is expected to trigger the downward adjustment of the conversion price [1] - If the downward adjustment clause for "Jiet Convertible Bonds" is triggered, the company's board will convene to decide whether to exercise the downward adjustment rights and will fulfill its information disclosure obligations in a timely manner [1]

Core Viewpoint - The company has decided not to adjust the conversion price of its convertible bonds, despite triggering the downward adjustment clause due to stock price performance [2][7]. Group 1: Convertible Bond Details - The company issued 4.4 million convertible bonds at a face value of 100 RMB each, raising a total of 440 million RMB [3]. - The initial conversion price was set at 48.23 RMB per share, which was adjusted to 48.09 RMB on June 6, 2023, and further adjusted to 48.02 RMB on July 4, 2024, and to 47.95 RMB on July 2, 2025 [4]. - The downward adjustment clause is triggered when the stock price is below 85% of the conversion price for at least 15 out of 30 consecutive trading days [5]. Group 2: Board Decision - The board of directors convened on August 1, 2025, and unanimously agreed not to adjust the conversion price, with all related directors abstaining from the vote [8][9]. - The decision will remain in effect for three months, until November 1, 2025, during which time the company will not propose any downward adjustment even if the clause is triggered again [7][9].

Group 1 - The company held its 22nd meeting of the 4th Board of Directors on August 1, 2025, with all 7 participating directors voting unanimously [1] - The Board approved the proposal not to lower the conversion price of the "Jietai Convertible Bonds," with 4 votes in favor and no opposition or abstentions [1] - Related directors recused themselves from the voting process [1] Group 2 - The company will not propose a downward adjustment to the conversion price within the next three months, from now until November 1, 2025 [2] - If the conversion price adjustment clause is triggered again after November 2, 2025, the Board will reconvene to decide on the adjustment [2] - Further details are available in the announcement published on the Shanghai Stock Exchange website [2]

Core Viewpoint - The company, JieTe Bio, announced that its board of directors has approved a proposal not to lower the conversion price of its convertible bonds, known as "JieTe Convertible Bonds" [2] Group 1 - The fourth meeting of the fourth board of directors took place on August 1, where the proposal was reviewed and approved [2]

Core Points - Jiet Bio (688026) closed at 15.86 yuan on June 27, 2025, up 5.17% from the previous week's 15.08 yuan [1] - The company's total market capitalization is 2.226 billion yuan, ranking 116th out of 126 in the medical device sector and 4825th out of 5151 in the A-share market [1] Company Announcements - Jiet Bio announced the interest payment for "Jiet Convertible Bonds" for the year 2025, with a face value of 100 yuan per bond and an interest amount of 1.00 yuan (including tax) [1] - The bond interest record date is June 27, 2025, with the ex-dividend date and payment date set for June 30, 2025 [1] - The company issued 4.4 million convertible bonds in June 2022, raising a total of 440 million yuan, with a six-year term and an increasing interest rate, reaching 1.00% in the third year [1] - The interest payment for this period covers from June 28, 2024, to June 27, 2025, with a net interest distribution of 0.80 yuan after a 20% personal income tax [1]